1. Immunometabolic Dysfunction of Natural Killer Cells Mediated by the Hypoxia-CD73 Axis in Solid Tumors
   Andrea M. Chambers et al, 2019, Frontiers in Molecular Biosciences CrossRef
2. Immune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit
   Kourtney L. Kostecki et al, 2024, Cancers CrossRef
3. CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model
   Hidenori Tsukui et al, 2020, BMC Cancer CrossRef
4. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways
   Alexandra Giatromanolaki et al, 2020, Life Sciences CrossRef
5. CD73 facilitates invadopodia formation and boosts malignancy of head and neck squamous cell carcinoma via the MAPK signaling pathway
   Feifei Xue et al, 2022, Cancer Science CrossRef
6. Tregs: Where We Are and What Comes Next?
   Hai Zhao et al, 2017, Frontiers in Immunology CrossRef
7. Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival
   Jun Zhao et al, 2021, Pancreatology CrossRef
8. A Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule Inhibitors of CD73 with Diverse Inhibition Modalities
   Jessica McManus et al, 2018, SLAS Discovery CrossRef
9. CD73 is associated with poor prognosis in HNSCC
   Zhen-Hu Ren et al, 2016, Oncotarget CrossRef
10. Purinergic Receptors: Novel Targets for Cancer Immunotherapy
    Dipti Vijayan et al, 2018, Oncoimmunology CrossRef
11. CD8+CD73+ T cells in the tumor microenvironment of head and neck cancer patients are linked to diminished T cell infiltration and activation in tumor tissue
    Soumya Panigrahi et al, 2020, European Journal of Immunology CrossRef
12. Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?
    Linsen Shi et al, 2018, International Immunopharmacology CrossRef
13. CD73 Overexpression Promotes Progression and Recurrence of Papillary Thyroid Carcinoma
    Young Mun Jeong et al, 2020, Cancers CrossRef
14. If small molecules immunotherapy comes, can the prime be far behind?
    Jingyu Zhang et al, 2021, European Journal of Medicinal Chemistry CrossRef
15. CD73 expression in lymph node metastases in patients with head and neck cancer
    Magis Mandapathil et al, 2018, Acta Oto-Laryngologica CrossRef
16. Variability in CD39 and CD73 protein levels in uveal melanoma patients
    Olivier Harou et al, 2022, Nucleosides, Nucleotides & Nucleic Acids CrossRef
17. Antitumoral Action of Resveratrol Through Adenosinergic Signaling in C6 Glioma Cells
    Alejandro Sánchez-Melgar et al, 2021, Frontiers in Neuroscience CrossRef
18. Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers
    Tao Jiang et al, 2018, BMC Cancer CrossRef
19. Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future
    Yi Huang et al, 2019, Purinergic Signalling CrossRef
20. CD73 Is an Immunometabolic Biomarker of Poor Prognosis in Patients With Primary Cutaneous Squamous Cell Carcinoma and Hematologic Malignancy
    Vahide Saeidi et al, 2024, Dermatologic Surgery CrossRef